Asia-Pacific API Intermediates Market, By Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End-User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others) – Industry Trends and Forecast to 2030.
Asia-Pacific API Intermediates Market Analysis and Size
Asia-Pacific API intermediates market has experienced significant growth due to the high burden of chronic disorders and increase in aging population are the major drivers which propelled the demand of the market.
Data Bridge Market Research analyses that the Asia-Pacific API intermediates market which was USD 6,914.12 million in 2022, is expected to reach USD 12,034.12 million by 2030, and is expected to undergo a CAGR of 7.0% during the forecast period of 2023 to 2030. “Veterinary Drug Intermediates Pharmaceutical” dominates the product type segment of the Asia-Pacific API Intermediates market due to more demand of API across the world. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific API Intermediates Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End-User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Sanofi (France), Aarti Industries Limited (India), Aurobindo Pharma (India), Divi's Laboratories Limited (India), HIKAL Ltd. (India), Sandoz International GmbH (Germany), BASF SE (Germany), Cambrex Corporation (U.S.), AlzChem Group AG (Germany), Vasudha Pharma (India), Anyang General Chemical Co., Ltd. (South Korea), Sarex (India), Sandoo Pharmaceuticals and Chemicals Co., Ltd. (China), Atul Ltd. (India), Aceto (U.S.), Supriya Lifescience Ltd. (India), Vertellus (U.S.), Dishman Carbogen Amcis Ltd (Switzerland/India), Ganesh-Group (India), Levachem Company Limited (China) and among other
|
|
Market Opportunities
|
|
Market Definition
Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others.
Asia-Pacific API Intermediates Market Dynamics
Drivers
- Growing Pharmaceutical Industry
The Asia-Pacific region has witnessed substantial growth in its pharmaceutical industry. Factors such as an aging population, increasing healthcare expenditures, and rising prevalence of chronic diseases drive the demand for pharmaceuticals, thereby boosting the API intermediates market.
- Rising Generic Drug Manufacturing
The region is a prominent hub for generic drug manufacturing. Generic drugs require a constant supply of API intermediates, as they offer cost-effective alternatives to brand-name medications. The expanding generic drug market is a significant driver of API intermediate’s demand.
- Increasing Contract Manufacturing
The trend of outsourcing drug manufacturing to contract development and manufacturing organizations (CDMOs) has gained momentum in the Asia-Pacific region. Pharmaceutical companies, particularly those engaged in research and development, often choose to partner with CDMOs to streamline their operations and focus on core competencies. CDMOs rely on a stable and reliable supply chain, which includes API intermediates suppliers. Ensuring a consistent flow of quality intermediates is vital for CDMOs to meet their client’s needs efficiently. This demand from CDMOs fuels the growth of API intermediates manufacturers.
Opportunities
- Development and Adoption of Biopharmaceuticals and Biosimilar
The Asia-Pacific region has seen a surge in the development and adoption of biopharmaceuticals and biosimilar. These complex molecules often require specialized API intermediates for their production. This presents an opportunity for manufacturers to cater to the specific needs of biopharmaceutical companies. Biopharmaceuticals include monoclonal antibodies, gene therapies, and cell-based therapies, which are gaining prominence in treating various diseases. Manufacturers can invest in the research and development of API intermediates tailored to biopharmaceutical applications.
-
Emerging and Markets Expansion
Expanding into emerging markets within the Asia-Pacific region offers significant growth opportunities for API intermediates manufacturers. Countries in Southeast Asia, for instance, are experiencing increased healthcare spending and greater access to healthcare services. These emerging markets represent untapped potential for API intermediates, as pharmaceutical production and research activities expand to meet the growing healthcare needs of their populations. Establishing a presence in these markets can lead to increased demand for intermediates.
Restraints/Challenges
- Regulatory Challenges in API Production
The pharmaceutical industry is highly regulated to ensure patient safety and product quality. Compliance with various international and national regulations and quality standards is mandatory, making regulatory adherence a complex and expensive process. API intermediates manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and undergo rigorous inspections and audits to maintain compliance. Regulatory changes, such as updates to quality standards or new compliance requirements, can pose challenges for manufacturers. Meeting these requirements often requires significant investments in infrastructure, technology, and human resources.
- Competition from Low-Cost Producers
The Asia-Pacific region is home to countries known for their cost-effective manufacturing capabilities, such as China and India. These countries have a competitive advantage due to lower labor and operational costs. As a result, they can produce API intermediates at a lower price point than manufacturers in other regions. This intense price competition can squeeze profit margins for API intermediates manufacturers operating in higher-cost locations. To remain competitive, manufacturers must focus on factors such as product quality, innovation, and service differentiation.
This Asia-Pacific API Intermediates market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific API Intermediates Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In January 2021, Vertellus has been acquired by the company, Pritzker Private Capital who partners with the middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered as leading company or provider of specialty chemicals in different sectors such as healthcare, food and agriculture, personal care, transportation and coatings, so PPC has made a partnership with the company. This helped the company Vertellus to increase their market growth which will drive revenues of the company.
Asia-Pacific API Intermediates Market Scope
The Asia-Pacific API intermediates market is segmented on the basis of type, product, therapeutic type, customers, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Veterinary Drug Intermediates Pharmaceutical
- Bulk Drug Intermediates
Product
- Bromo Compound
- O-Benzyl Salbutamol
- Hemisulfate
- Oxirane
- Bisoprolol Base
- Chiral PCBHP
- Pheniramine Base
- Chlorpheniramine Base
- Brompheniramine Base
- Mepyramine/Pyrilamine Base
- 6-Amino-1,3-Dimethyl Uracil
- Theofylline
- Acefylline
- Xanthine
- Nitriles
- Others
Therapeutics Type
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Dermatology
- Urology
- Others
Customers
- Direct Users/Pharma Companies
- Traders/Wholesalers/Distributors
- Associations/Govt. Institutions/Pvt Institutions
End-Users
- API Manufacturer
- Finished Product Manufacturer
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Asia-Pacific API Intermediates Market Regional Analysis/Insights
The Asia-Pacific API Intermediates market is analysed and market size insights and trends are provided by type, product, therapeutic type, customers, end-users, and distribution channel as referenced above.
The countries covered in the Asia-Pacific API intermediates market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific (APAC).
China is leading the growth of the Asia-Pacific region and pharmaceutical/bulk drug intermediates segment is dominating in this country because China is the highest active pharmaceutical ingredient producer globally. India is the fastest growing country due to rising government initiatives for the production of APIs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific API Intermediates Market Share Analysis
The Asia-Pacific API intermediates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific API intermediates market.
Some of the major players operating in the Asia-Pacific API intermediates market are:
- Sanofi (France)
- Aarti Industries Limited (India)
- Aurobindo Pharma (India)
- Divi's Laboratories Limited (India)
- HIKAL Ltd. (India)
- Sandoz International GmbH (Germany)
- BASF SE (Germany)
- Cambrex Corporation (U.S.)
- AlzChem Group AG (Germany)
- Vasudha Pharma (India)
- Anyang General Chemical Co., Ltd. (South Korea)
- Sarex (India)
- Sandoo Pharmaceuticals and Chemicals Co., Ltd. (China)
- Atul Ltd. (India)
- Aceto (U.S.)
- Supriya Lifescience Ltd. (India)
- Vertellus (U.S.)
- Dishman Carbogen Amcis Ltd (Switzerland/India)
- Ganesh-Group (India)
- Levachem Company Limited (China)
SKU-